Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.
CD8-Positive T-Lymphocytes
/ immunology
Cancer Vaccines
/ immunology
Cell Differentiation
/ immunology
Cell Movement
/ immunology
Cells, Cultured
Chemokines
/ immunology
Dendritic Cells
/ cytology
Gene Expression Regulation
/ immunology
Humans
Immunity, Innate
Lymphocyte Activation
Melanoma
/ immunology
Receptors, CXCR3
/ immunology
Skin Neoplasms
/ immunology
T-Lymphocytes
/ immunology
DC vaccines
cDC2
chemokines
migration
pDC
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
28 01 2020
28 01 2020
Historique:
received:
27
08
2019
revised:
26
11
2019
accepted:
27
12
2019
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
21
10
2020
Statut:
ppublish
Résumé
Plasmacytoid dendritic cells (pDCs) and type 2 conventional dendritic cells (cDC2s) are currently under evaluation for use in cancer vaccines. Although both DC subsets can activate adaptive and innate lymphocytes, their capacity to recruit such cells is rarely considered. Here, we show that pDCs and cDC2s display a striking difference in chemokine secretion, which correlates with the recruitment of distinct types of immune effector cells. Activated pDCs express high levels of CXCR3 ligands and attract more CD8
Identifiants
pubmed: 31995747
pii: S2211-1247(19)31761-9
doi: 10.1016/j.celrep.2019.12.096
pii:
doi:
Substances chimiques
CXCR3 protein, human
0
Cancer Vaccines
0
Chemokines
0
Receptors, CXCR3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027-1038.e4Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests The authors declare no competing interests.